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Angiotensin receptor blockerCD14 is a predictor of inﬂammation and associated with atherosclerosis. We analyzed 118 carotid plaques from
patients with symptomatic carotid artery stenosis for expression of themacrophagemarkers CD14, CD68 and the
angiotensin II type 1 receptor (AT1-R). CD14 staining was signiﬁcantly increased in thrombotic carotid plaques.
AT1-R staining was found in macrophage-rich areas, and AT1-R mRNAwas detected in plaque macrophages iso-
latedwith anti-CD14 immunobeads. In patients treatedwith an angiotensin receptor blocker, expression of CD14
and CD68 in carotid plaque and serum levels of inﬂammatory markers were lower than in untreated patients. In
vitro, expression of CD14 in human monocyte-derived macrophages was increased by exposure to lipopolysac-
charide and decreased by exposure to an angiotensin receptor blocker. Thus, inhibition of the innate immune
responsive lipopolysaccharide receptor CD14 in macrophages, rather than AT1-R inhibition, may help explain
the anti-inﬂammatory effects of angiotensin receptor blockade.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Bacteria predominantly affect atherosclerosis by activating the
innate immune system in atherosclerotic plaques [1]. The innate
immune system, which provides the initial inﬂammatory response to
infection, requires the recognition of speciﬁcmicrobial antigens, includ-
ing the endotoxin lipopolysaccharide (LPS), a major component of the
outer membranes of gram-negative bacteria. Recognition of LPS by the
innate immune system leads to immediate cell activation and increased
expression of membrane-anchored CD14 on monocytes/macrophages.
Binding of LPS to CD14 triggers inﬂammation and activates the
transcription factor nuclear factor kappa B and the toll-like receptor
pathway, initiating the release of proinﬂammatory cytokines into the
vasculature, a characteristic of hypertension and atherosclerosis [2–4].
Macrophages play amajor role in the development of atherosclerosis.
Macrophages within human atherosclerotic lesions are predominantly
CD68- and CD14-positive [5] and colocalize with the angiotensin II type
1 receptor (AT1-R) [6]. The renin–angiotensin system is associated with
vascular inﬂammation, recruitment of inﬂammatory cells into the vessel
wall, arterial remodeling, arterial calciﬁcation, and hypertension [7–9]. IngrenskaUniversity Hospital, SE-
+46 31 823762.
ultén).
. This is an open access article undervivo, AT1-R activity is necessary for a complete response to LPS [10]. AT1-
R activity regulates some of the mechanisms underlying the effects of
LPS, suggesting that mechanisms related to angiotensin II activation
may interfere with CD14 signaling and affect expression of pro-
inﬂammatory factors [10].
Here we investigated the expression of CD14 and AT1-R in human
carotid endarterectomies. We also studied the effects of LPS and an
AT1-R blocker (ARB) on CD14 expression in human monocyte-derived
macrophages.
2. Materials and methods
2.1. Human carotid endarterectomies
Carotid endarterectomies from 118 patients with high-grade
symptomatic carotid artery stenosis, deﬁned as ≥70% stenosis accord-
ing to European Carotid Surgery Trial criteria [11], were obtained from
the Göteborg and Umeå Vascular Study Biobank (http://www.wlab.gu.
se/bergstrom/guvasc/). Patient characteristics are shown in Table 1.
Immunohistochemical staining was done with mouse monoclonal
antibodies against CD14 (1:25), CD68 (1:500, Leica Novocastra), AT1-R
(1:30, Abcam), and CD42 (1:200, Dako, Glostrup, Denmark). Antibodies
were detected with Mach3 kit and Vulcan Fast Red (Biocare Medical).
Stained sections were digitalized with a Zeiss Mirax Scanner (Zeiss),the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Baseline characteristics and AHA class of plaque.
Characteristic
Female, n (%) 32 (27)
Male, n (%) 86 (73)
Age, years, mean ± SD 68.8 ± 21.5
Clinical event
Stroke, n (%) 62 (53)
Transient ischemic attack, n (%) 30 (25)
Amaurosis fugax, n (%) 26 (22)
Hypertension, n (%) 80 (68)
Diabetes, n (%) 37 (31)
Smoker, n (%) 42 (36)
ASA therapy, n (%) 84 (90)
Statin therapy, n (%) 84 (71)
ARB therapy, n (%) 23 (19)
Blood pressure, mm Hg
Systolic, mean ± SEM 149 ± 45
Diastolic, mean ± SEM 78.8 ± 33.5
American Heart Association class
Class 3, n (%) 4 (3)
Class 4, n (%) 37 (31)
Class 5, n (%) 18 (15)
Class 6, n (%) 59 (50)
ASA, acetylsalicylic acid.
319C. Hermansson et al. / International Immunopharmacology 22 (2014) 318–323and the imageswere analyzedwith BioPix software (BioPix). The extent
of immunohistochemical staining was expressed as a percentage of the
stained area of the total section area.
Thrombus formation was deﬁned as rupture of the ﬁbrous cap with
clear communication between the necrotic core and the lumen and
adjacent surface thrombus, as described [12]. For histopathological
classiﬁcation of plaques according to the American Heart Association
(AHA) classiﬁcation [13], deparafﬁnized serial sections were stained
with Mayer's hematoxylin and eosin (Histolab) and examined with a
Zeiss Axio Imager M1 microscope.2.2. Isolation of plaque macrophages
Aortic tissue from ﬁve different carotid specimenswas digestedwith
collagenase, and macrophages were isolated by incubation with anti-
bodies against the macrophage surface marker CD14 (BD Biosciences)
as described [14]. Speciﬁcally, pretreated cells mixed with magnetic
Dynabeads coated with sheep anti-mouse IgG (Life Technologies), and
the target cells were isolated with a magnet. Cells were washed several
times with phosphate-buffered saline, and the absence of negative cells
was conﬁrmed by light microscopy. RNAwas extracted from the isolat-
ed CD14-positive cells. The study protocol was approved by the Ethical
Committee of the University of Gothenburg (Dnr. 404-09) and all
subjects gave written informed consent.2.3. Primary human monocyte-derived macrophages
Buffy coats were obtained from the local blood bank at Kungälv Hos-
pital, Sweden, and human mononuclear cells were isolated by centrifu-
gation in a discontinuous gradient of Ficoll-Paque (GE Healthcare). Cells
were seeded in macrophage serum-free medium (Life Technologies)
containing granulocyte macrophage colony-stimulating factor (GM-
CSF). After 3 days, the medium was changed to RPMI 1640 medium
without GM-CSF and cells were cultured for 7 days before experiments.
To investigate the effect of inﬂammation, macrophages were incubated
with and without LPS 0.1 μg/mL (Sigma), and with and without the
ARB, candesartan 0.1 μmol/L (Sigma) for 24 h before collection of cell
culture supernatant and extraction of RNA.2.4. Analysis of gene expression
RNA was isolated with the RNeasy kit (Qiagen). Expression of
human CD14 mRNA was determined by quantitative real-time PCR
and normalized to β-actin mRNA expression. The reverse transcription
reaction was set up with a cDNA reverse transcription kit (#4368814)
and performed with a PCR system (Gene Amp 9700, Applied
Biosystems). Real-time PCR ampliﬁcation was set up using TaqMan
gene expression assays for human CD14 (Hs02621496_s1), AT1-R
(Hs00258938_m1), human actin B (Hs99999903_m1) in combination
with Universal PCR master mix (#4324018) and performed for 50 cy-
cles on an ABI Prism 7900 HT sequence detection system (Applied
Biosystems).
2.5. Measurement of inﬂammatory markers
C-reactive protein (CRP) was measured in serum with an ultrasensi-
tive particle-enhanced immunoturbidimetric method (Orion Diag-
nostica) and a Konelab 20 autoanalyzer (Thermo Fisher Scientiﬁc).
Serum IL-6 was measured with a Quantikine ELISA kit (R&D Systems).
For analysis of the secreted cytokines interferon-γ, interleukin (IL)-1β,
IL-2, IL-6, IL-8, IL-12p70, and tumor necrosis factor-α in cell culture
supernatants from primary human macrophages, we used a human
proinﬂammatory multiplex assay (Meso Scale Discovery) and a Sector
Imager 2400 reader (Meso Scale Discovery), according to the
manufacturer's instructions.
2.6. Statistics
Values are mean ± SEM. All analyses were performed with
GraphPad Prism version 5.01 forWindows (GraphPad Software). Corre-
lations between CD14, AT1-R and CD68 were assessed by the Spearman
rank correlation test. For evaluation of the treatment effect of ARB vs.
not treated with ARB, we used Wilcoxon signed rank test. One-way
ANOVA followed by Tukey's test for multiple comparisons and Students
t-test was used for comparison between two groups. Values of P b 0.05
were considered signiﬁcant.
3. Results
3.1. Macrophage CD14 staining associates with complicated lesions
Patient and plaque characteristics are shown in Table 1. Of the 118
patients, 62 had suffered a stroke, 30 had a transient ischemic attack
(TIA), and 26 had amaurosis fugax. Classiﬁcation of the plaques accord-
ing to AHA criteria is shown in Table 1.
To determine whether bacteria activate the innate immune system
in atherosclerotic plaque, we analyzed the LPS receptor CD14 in 118
carotid plaques. The extent of CD14 staining was higher in the most
severe lesion phenotypes (AHA VI) with a ruptured ﬁbrous cap and/or
thrombosis (Fig. 1A, B). CD14 staining was higher in 45 plaques with
evidence of thrombosis than in plaques without thrombosis (Fig. 1C).
3.2. Expression of AT1-R colocalizes with macrophages in human carotid
atherosclerotic plaques
AT1-R expression colocalized with expression of both CD14 and CD68
(Fig. 2A–C). All three proteins were often expressed in the shoulder
region of the plaque (Fig. 2A–C). The extent of AT1-R staining correlated
with CD14 (Fig. 2D) and CD68 (Fig. 2E) staining. To study expression of
AT1-R mRNA in plaque macrophages, we isolated CD14-positive macro-
phages from carotid endarterectomies. AT1-R expression correlated
with CD14mRNA expression (Fig. 2F). These ﬁndings suggest that AT1-R
expression in plaque macrophages is associated with activation of CD14
by bacterial LPS.
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Fig. 1. CD14 is present in atherosclerotic plaques. Serial sections of atherosclerotic carotid
artery plaques of patients with symptomatic carotid artery stenosis (n = 118) were
stained with antibodies against CD14 and counterstained with Mayer's hematoxylin.
(A) Representative section stained for CD14. (B) CD14 staining in 4 AHA class III plaques,
37 class IV plaques, 18 class V plaques, and 59 class VI plaques. AHA class VI indicates com-
plicated lesions with ruptured ﬁbrous cap and/or surface thrombus. (C) CD14 staining in
plaques with thrombosis (n = 46) and without thrombosis (n = 74) Values are mean ±
SEM. Data were analyzed using (B) one-way ANOVA (P = 0.0086) followed by Tukey's
test formultiplecomparisons(*Pb0.05AHA6vs.AHA4)and(C) Students t-test ***P= 0.0007.
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In macrophages from lesion areas in plaques from patients receiving
treatment with ARB, staining for CD14, CD68, and AT1 was reduced
(Fig. 3A), but there was no change in the level of α-actin (a marker of
plaque stability) (Fig. 3B). Stroke was diagnosed in 26% of ARB-treated
patients and 35% of those not treated with ARB. To evaluate the anti-
inﬂammatory role of ARB, we also measured cytokine levels in serum
from patients treated with ARB and those who were not. The treated
patients had lower plasma levels of CRP and IL-6 (Fig. 3C), suggesting
that ARB decreases systemic inﬂammation.3.4. ARB decreases CD14 expression and cytokine secretion in human
primary macrophages
To ascertain whether activation of macrophages by LPS affects CD14
and AT1-R expression, macrophages were cultured for 24 h with and
without LPS. LPS increased CD14 expression in all seven blood donors
tested (Fig. 4A). However, LPS increased AT1-R mRNA expression in
two of the seven donors and was below the detection level in ﬁve
samples (Fig. 4B). Treatment of human primary macrophages with
LPS and ARB reduced CD14 mRNA expression to approximately 50% of
the levels in the presence of LPS (Fig. 4A). AT1-R mRNA expression
was reduced in two of seven donors, increased by ARB in two donors,
and was below the detection limit in three donors (Fig. 4B). Thus, ARB
reduced CD14 expression but had no consistent effect on AT1-R mRNA
expression in primary macrophages. LPS increased cytokine secretion
in human primary macrophages; in the presence of ARB, levels of
interferon-γ, IL-1β, and IL-8 in the cell culture medium were reduced,
and levels of IL-2, IL-6, IL-10, IL-12p70, and tumor necrosis factor-α
were unchanged (Fig. 4C–J), indicating that ARB affects secretion of
proinﬂammatory cytokines.
4. Discussion
This study shows that CD14 expression in the carotid artery wall of
human atherosclerotic plaques colocalizes with CD68-positive macro-
phages and AT1-R expression. Plaques with high expression of CD68
and CD14 often showed signs of thrombosis. Furthermore, ARB-treated
patients had lower serum levels of CRP and IL-6 and lower expression
of CD14, CD68, and AT1-R in their plaques. Finally, CD14 expression
was increased in primary human monocyte-derived macrophages
exposed to LPS, and the increase was inhibited by ARB. Thus, ARB treat-
ment reduces inﬂammatory activation and CD14 expression in human
primary macrophages.
CD14 is a surface antigen that is preferentially expressed on mono-
cytes/macrophages. It cooperates with other proteins to mediate the
innate immune response to bacterial LPS. CD14 predicts incident cardio-
vascular disease and mortality in older adults [15]. High expression of
CD14 on circulating monocytes is associated with acute and subacute
phases of ischemic stroke [16]. CD14 is expressed in both membrane-
anchored and soluble forms onmonocytes/macrophages [15,17]. Soluble
CD14 levels are associated with both subclinical vascular disease (carotid
intima-media thickness and ankle-brachial index) and with risk of
future clinical cardiovascular disease in older adults, independently of
other risk factors [15].
It is difﬁcult to distinguish whether higher levels of soluble CD14 or
other inﬂammatorymediators are directly causal or indicative of chron-
ic, low-level infection and other immune alterations, or simply reﬂect
worsening subclinical and clinical disease. Nonetheless, soluble CD14
might be clinically useful as a marker of disease risk or disease progres-
sion [15].
Our results show that LPS-mediated macrophage activation and
CD14 expression correlate with thrombosis in carotid plaques. This is
interesting, as isolated circulatingmicrovesicles that contain CD14 stim-
ulate thrombus formation [18]. In addition platelet–monocyte interac-
tions were evident in CD14-positive monocytes and were associated
with poor outcome and harmful effects after stroke, including stronger
interaction with platelets [19]. LPS-activated macrophages expressing
CD14 are pro-coagulant and may be associated with increased risk for
thrombosis and clinical events.
Macrophage express a complete renin–angiotensin system, includ-
ing the AT1-R, and angiotensin activates macrophages, which may
have consequences for atherosclerotic plaque rupture [20]. We found
that bacterial activation of CD14 and AT1-R expression are associated
with complicated lesions. Most of the deleterious effects of the renin–
angiotensin system in atherosclerosis are believed to be mediated
through stimulation of the AT1-R [7,21,22]. Interestingly, angiotensin
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Fig. 2. AT1-R is expressed in the shoulder region of human carotid atherosclerotic plaques. Representative images of serial sections of atherosclerotic plaques stained with antibodies
against AT1-R (A), CD14 (B), and CD68 (C). The AT1-R stained area correlated with expression of both the proinﬂammatorymacrophagemarkers CD14 (D) and CD68 (E). (F) Expression
of AT1 and CD14 mRNA in isolated plaque macrophages from ﬁve human carotid endarterectomies. Data were analyzed using Spearman's rank correlation test.
321C. Hermansson et al. / International Immunopharmacology 22 (2014) 318–323II, angiotensin-converting enzyme, and AT1-R co-localize with macro-
phages in human coronary atheromata, and are present in
macrophage-rich areas of human carotid artery plaques [6,23].
The precise mechanisms leading to AT1-R expression in the hypertro-
phic intima of atherosclerotic disease are still partly unknown, as is the
exact function of the AT1-R presence in atheromata. Our ﬁndings provide
insights into the circumstances of AT1-R expression, as we found that
AT1-R protein expression increases in macrophages after differentiation.
Consistent with this ﬁnding, when THP-1 monocyte-like human leuke-
mia cells were induced to differentiation intomacrophageswith phorbol
12-myristate 13-acetate, AT1-R expression increased [24]. The renin–an-
giotensin system is activated during monocyte/macrophage differentia-
tion, and may contribute to the development of atherosclerosis [8]. We
detected AT1-R mRNA in CD14-positive macrophage preparations isolat-
ed from carotid endarterectomies. Moreover, AT1-R mRNA expression
was increased in LPS-activated primary macrophages from some donors
and was not detectable in macrophages from other donors. This variabil-
ity in AT1-R expression in macrophages and their responses to LPS and
ARB suggest individual variations in AT1-R expression.Our results show that ARB reduces CD14 and it is established that the
anti-inﬂammatory effects of ARBs have beneﬁcial effects in inﬂammatory
disorders [10]. The mechanisms by which the ARB decreases LPS inﬂam-
matory effects are not clear. It has been reported that ARB reduces oxida-
tive stress, decreases reactive oxygen species and CRP levels in
hypertensive patients [25]. Here we show that ARB reduces LPS-
mediated expression of CD14 and decreases production of proinﬂamma-
tory markers. The reduction of inﬂammation by ARB may be a conse-
quence of decreased oxidative stress [25,26]. Interestingly, ARB limits
the monocyte response to LPS in the absence of AT1-R expression, and
the anti-inﬂammatory effects of ARB appear to be independent of its
AT1-R blocking properties [27]. Dialysis patients who were treated with
ARB showed lower levels of CD14+CD16+ monocytes and lower
plasma levels of pro-inﬂammatory cytokine than patients not treated
with ARB [28]. These ﬁndings are in agreement with our results. We sug-
gest that the anti-inﬂammatory effect of ARB is independent of its AT1-R
blocking activity and is instead associated with the reduction of CD14
expression on macrophages. Thus, ARB may have anti-inﬂammatory
effects and may inhibit the innate immune response to bacterial LPS.
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Fig. 3. Extent of immunostaining in human carotid plaques frompatients treatedwith ARB
or not. (A) Staining of macrophages for CD14, CD68, and AT1-R. (B) Staining forα-actin, a
marker of plaque stability. (C) Serum levels of the inﬂammatory markers CRP and IL-6 in
ARB-treated and untreated patients. Data were analyzed usingWilcoxon signed rank test
to compare the treatment effect of ARB (P b 0.0001) vs. not treated with ARB (A and C).
322 C. Hermansson et al. / International Immunopharmacology 22 (2014) 318–323In summary, bacterial activated CD14-positive macrophages are
found in complicated atherosclerotic lesions, and AT1-R blockade inhibits
LPS-induced innate immune responses and may be considered for the
treatment of bacterial inﬂammatory conditions. The ﬁnding that bacterial
activation of CD14 increases the risk for thrombotic eventsmay guide the
development of preventive strategies to reduce the risk of vascular
events and mortality by lowering CD14 expression with ARB.
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Fig. 4. Effect of ARB on CD14 and AT1-R expression and cytokine production in LPS-activated humanmonocyte-derived macrophages. Humanmononuclear cells were cultured with and
without LPS and with ARB for 24 h. (A–J) Expression levels of CD14 mRNA (A), AT1-R mRNA (B), interferon (IFN)-γ (C), IL-1β (D), IL-2 (E), IL-6 (F), IL-8 (G), IL-10 (H), IL-12p70 (I), and
tumor necrosis factor (TNF)-α (J) inmacrophage culturemedium. Values aremean± SEM (n=7macrophage donors). Datawere analyzed using one-way ANOVA (P b 0.001 for A and C,
D, F, G and P b 0.05 for E, H–J) followed by Tukey's test for multiple comparisons (*P b 0.05, **P b 0.01 and ***P b 0.001).
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